Empagliflozin	Placebo	Risk of death by cardiovascular causes	685	879	The risk of CV death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001) and the risk of death from any cause by 32% (HR 0.68; 95% CI: 0.57–0.82; P < 0.001).
Empagliflozin	Placebo	Risk of death by any cause	685	879	The risk of CV death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001) and the risk of death from any cause by 32% (HR 0.68; 95% CI: 0.57–0.82; P < 0.001).
Empagliflozin	Placebo	Risk of death by cardiovascular causes	685	794	The risk of CV death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001)
Empagliflozin	Placebo	Risk of hospitalization due to heart failure or renal adverse events.	33177	33257	The reduction in the risk of hospitalization for heart failure was also striking
Empagliflozin	Placebo	Risk of major adverse cardiovascular events	460	684	The risk of major adverse CV events (MACE: first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke) was reduced by 14% relative to placebo (HR 0.86; 95.02% CI: 0.74–0.99; P = 0.04 for superiority).
Empagliflozin	Placebo	Risk of hospitalization due to heart failure or renal adverse events.	893	1005	empagliflozin was associated with reduced risk of hospitalization for heart failure and of renal adverse events.
Empagliflozin	Placebo	Risk of death by any cause	685	878	The risk of CV death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001) and the risk of death from any cause by 32% (HR 0.68; 95% CI: 0.57–0.82; P < 0.001)
